All In Biotech

Drug Trial Radar · NCT07251595

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR0302 Tablets as Single Therapy or in Combination With SHR0302 Base Gel in the Treatment of Patients With Non-segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Mar 2027

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

  • SHR0302 TabletsDrug

    SHR0302 tablets.

  • SHR0302 Base GelDrug

    SHR0302 Base gel.

  • SHR0302 Placebo TabletsDrug

    SHR0302 placebo tablets.

  • SHR0302 Base Placebo GelDrug

    SHR0302 Base placebo gel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change in the facial vitiligo area score index (F-VASI) from the baseline.Time frame: At Week 24.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital affiliated to Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.